Drug
Tulisokibart clinical trials
Also written MK-7240 and PRA023.
- studies test it
- 16
- open now
- 5
- in phase 3
- 3
- first study started
- 2020
Keep track of what changes. Save the tulisokibart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 8
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 0
Merck Sharp & Dohme LLC (12) · Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (4)
Studies
Open first, then newest update. How each study uses tulisokibart is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06430801Written as IV Tulisokibart
- A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07133633Written as Tulisokibart
- A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)Not yet recruitingPhase 2Merck Sharp & Dohme LLCNCT07867938Written as Tulisokibart
- A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)Not yet recruitingPhase 2Merck Sharp & Dohme LLCNCT07861074Written as Tulisokibart
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06651281Written as Tulisokibart
- Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT07486960Written as Tulisokibart
- A Study of MK-7240 in Healthy Participants (MK-7240-009)CompletedPhase 1Merck Sharp & Dohme LLCNCT07405177Written as Tulisokibart Form 1
- Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06956235Written as Tulisokibart
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06052059Written as IV Tulisokibart
- A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT07176390Written as Tulisokibart
- Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)Active, not recruitingPhase 2Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT05270668Written as Tulisokibart
- A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)CompletedPhase 2Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT04996797Written as Tulisokibart
- Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)CompletedPhase 1Merck Sharp & Dohme LLCNCT06575595Written as Tulisokibart
- Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT06829225Written as Tulisokibart
- A Study of PRA023 in Healthy VolunteersCompletedPhase 1Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT04676178Written as PRA023
- Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023CompletedPhase 1Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT05354349Written as PRA023 IV Low Dose
Given in every arm · 1 — tulisokibart is usual care beside what is tested
Codes
What other systems call tulisokibart · ClinicalTrials.gg INT017484
- UNII (FDA) ON09TCS5H3TULISOKIBARTOne source FDA
- NCI Thesaurus C190474TulisokibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ON09TCS5H3 | TULISOKIBART | One source FDA |
| NCI Thesaurus | C190474 | Tulisokibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.